CAR-T Referral Process: Insights from UCSF : Episode 5
CAR T-Cell Therapy: CAR T-Cell therapy Process and Bridging Therapy
Panelists discuss how CAR T-cell therapy involves engineering a patient’s T cells to target cancer cells. The process includes cell collection, genetic modification, expansion, and reinfusion and streamlines the process with integrated workflows. Bridging therapy is provided in-house to treat patients awaiting CAR-T infusion.
Video content above is prompted by the following:
- Could you explain how CAR T-cell therapy works and describe the treatment process?
- Do you consider CAR T-cell therapy a complex process at your institution, or have you been able to streamline the logistics and integration into clinical workflows?
- Can you explain your institution’s approach to bridging therapy for patients awaiting CAR T-cell manufacturing and infusion?
- Do you send patients back to the community center or does it happen in-house?
Recent Videos
Related Content
Considering NCCN Guidelines to Determine Maintenance Therapy Multiple Myeloma
February 15th 2025Article
During the 66th American Society of Hematology Annual Meeting and Exposition, experts in multiple myeloma gathered to discuss the impact of maintenance therapy and minimal residual disease (MRD) in patients with newly diagnosed transplant-eligible or -ineligible multiple myeloma.
